Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis

NCT ID: NCT03810573

Last Updated: 2024-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-01

Study Completion Date

2026-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this clinical study is to evaluate the safety and effectiveness of NB1 Bone Graft in subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion.

It is estimated that up to 30 participants will be enrolled in approximately 3 clinical sites. During baseline and follow-up assessments, patients will be asked to undergo x-rays and CT scans; adverse events and immunology will be collected, and; participants will be requested to complete participant questionnaires regarding quality of life, pain and function.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Degenerative Disc Disease Spondylolisthesis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NB1-1.5

NB1 low dose

Group Type EXPERIMENTAL

NB1

Intervention Type DEVICE

rhNELL-1/DBX

NB1-2.0

NB1 high dose

Group Type EXPERIMENTAL

NB1

Intervention Type DEVICE

rhNELL-1/DBX

Autograft

Autograft

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NB1

rhNELL-1/DBX

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented diagnosis of degenerative disc disease
* Up to Grade I spondylolisthesis
* Eligible to undergo a single vertebral level spine fusion (L2 to S1)

Exclusion Criteria

* Previous spinal instrumentation or previous interbody fusion procedure at the involved level
* Grade II or greater spondylolisthesis
* Systemic or local infection at the site of surgery
Minimum Eligible Age

17 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bone Biologics Corp

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tony Goldschlager, MD

Role: PRINCIPAL_INVESTIGATOR

Monash Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Monash Medical Center

Clayton, Victoria, Australia

Site Status RECRUITING

St Vincent Melbourne

Fitzroy, , Australia

Site Status RECRUITING

St George Hospital

Kogarah, , Australia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Australia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Brent Atkinson, PhD

Role: CONTACT

13035507866

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tony Goldschlager, MD

Role: primary

Terence Tan

Role: primary

Ashish Diwan

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NB1-100

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.